The document discusses the controversy around diagnosing and treating pediatric bipolar disorder. It notes that powerful psychiatric drugs are being prescribed to very young children for bipolar disorder despite lack of evidence of their effectiveness for this use and serious potential side effects. Pharmaceutical companies have financially supported expanding the diagnosis and use of their drugs off-label in children. Critics argue this has led to overdiagnosis and overprescribing driven more by commercial and social factors than medical science.